However, among the 25 AAV-G6pc−/− mice expressing <3% of normal hepatic G6Pase-α activity, four (16%) developed HCA/HCC, establishing that 3% normal hepatic G6Pase-α activity is the threshold for tumor prevention. This evidence concerns the gene G6PC1 and hepatocellular carcinoma.